Policy

• 

  Policy Matters

  Clinical Trial Endpoints for Timely Drug Development

  As patients live longer with cancer, scientists need to rethink how to determine if a new drug is safe and effective.

  by Kenneth Anderson, MD

• 

  Policy Matters

  Cancer Research Funding Faces Uncertain Future

  The AACR is planning numerous initiatives in 2024 to bolster congressional support.

  by Jon Retzlaff, MBA, MPA

• 

  Doctors Urge Need for ‘Common Sense Oncology’

  A movement of health care professionals say the toll of many cancer treatments is out of sync with the purported benefits.

  by Kyle Bagenstose

• 

  Policy Matters

  Taking Action to Support Cancer Research

  The AACR releases AACR Cancer Progress Report 2023, announces Cancer Centers Alliance, and joins 11th Rally for Medical Research.

  by Benjamin Krinsky, PhD

• 

  Policy Matters

  Clinical Trials That Reflect Real-world Patients

  A recent article discusses challenges and practical solutions for working toward more diverse and equitable oncology clinical trials.

  by Nicholas Warren, PhD

• 

  Policy Matters

  Reigniting the Moonshot

  President Biden proposes increased investment in cancer research and prevention to achieve the goals of the revised Cancer Moonshot.

  by Roy S. Herbst, MD, PhD

• 

  Policy Matters

  Stemming the E-Cigarette Epidemic

  An updated AACR-ASCO joint statement recommends steps for policymakers to lower e-cigarette use among youth and young adults.

  by Roy S. Herbst, MD, PhD

• 

  Q&A

  The FDA’s Risk-Benefit Framework

  Using the withdrawal of Avastin’s approval for breast cancer as a case study, Mikkael A. Sekeres’ new book analyzes the U.S. drug approval process.

  by Marci A. Landsmann

• 

  Policy Matters

  A Call to Eliminate Inequities

  The AACR Cancer Disparities Progress Report highlights the progress being made toward cancer health equity and stresses the need to address this complex public health issue.

  by Lisa A. Newman, MD, MPH

• 

  Forward Look

  FDA Designates Two Cigarettes as Modified Risk Tobacco Products

  Critics warn that lower nicotine content in the cigarettes may not translate into better odds of quitting.

  by Carisa Brewster